Compare AYTU & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYTU | BNGO |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 24.3M |
| IPO Year | N/A | 2018 |
| Metric | AYTU | BNGO |
|---|---|---|
| Price | $2.27 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $9.33 | $6.33 |
| AVG Volume (30 Days) | 88.9K | ★ 315.2K |
| Earning Date | 02-03-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,640,000.00 | $28,720,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $47.32 | $24.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.00 | N/A |
| 52 Week Low | $0.95 | $1.06 |
| 52 Week High | $3.07 | $6.32 |
| Indicator | AYTU | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 27.43 |
| Support Level | $2.28 | $1.06 |
| Resistance Level | $2.50 | $1.23 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 21.05 | 10.16 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.